- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Granules India Limited — Updates, 22-12-2025: Press Release
22-12-2025 | 07:47 am
22-12-2025 | 07:47 am
Granules' subsidiary received FDA Tentative Approval for generic ADHD drug, Amphetamine XR-ODT. The estimated market is $172 million (~1,428 Cr), with limited competition, boosting Granules' US generics portfolio and CNS presence.
No comments yet. Be the first to comment!